<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518685</url>
  </required_header>
  <id_info>
    <org_study_id>DTC006</org_study_id>
    <nct_id>NCT02518685</nct_id>
  </id_info>
  <brief_title>ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss</brief_title>
  <official_title>Endoscopic Treatment for Weight Reduction in Patients With Obesity Using the TransPyloric Shuttle® System: A Multicenter, Prospective, Randomized, Double-Blind, Sham-Controlled, Parallel-Design Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BaroNova, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BaroNova, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research trial is to study safety and effectiveness of the
      TransPyloric Shuttle System (TPSS) for weight reduction in patients who are considered
      medically obese.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group</measure>
    <time_frame>12 Months</time_frame>
    <description>The mean percent Total Body Weight Loss (% TBL) is the percentage weight change at 12 Months from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of TPS-treated Subjects With Weight Loss ≥ 5% TBL</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of subjects in the TPS group with ≥ 5% TBL is compared to a performance target of 50%</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>TransPyloric Shuttle (TPS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TransPyloric Shuttle plus Lifestyle Counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham procedure plus Lifestyle Counseling</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TransPyloric Shuttle</intervention_name>
    <arm_group_label>TransPyloric Shuttle (TPS)</arm_group_label>
    <other_name>TPS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Counseling</intervention_name>
    <description>The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>TransPyloric Shuttle (TPS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects between the ages of 22 to 60

          -  A BMI between 30.0 to 40.0 kg/m2, inclusive. Subjects with a BMI of 30.0 kg/m2 to 34.9
             kg/m2 are required to have one or more obesity-related comorbidities

          -  History of obesity for at least 2 years, with history of failure of medically or
             commercially supervised weight loss program

          -  &lt; 5% change in body weight for at least 3 months

          -  Negative pregnancy test, agree to be on birth control for the duration of
             participation

          -  Informed consent

          -  Willing and able to comply with study procedures

        Exclusion Criteria:

          -  Pregnancy or nursing

          -  Hormonal or genetic cause for obesity

          -  Prior history of any GI surgery or endoscopic intervention

          -  Chronic use of medications likely to contribute to weight gain or prevent weight loss

          -  Gastric or duodenal ulcers

          -  Positive for H. pylori

          -  History of severe dyspepsia

          -  GI tract motility disorders

          -  History of inflammatory disease of GI tract, coeliac disease, pancreatitis, portal
             hypertension, cirrhosis, and/or varices

          -  Diabetes treated with insulin

          -  HbA1c &gt;7.5%

          -  Uncontrolled thyroid and adrenal gland disease or uncontrolled hypertension

          -  History of certain cardiac events

          -  Localized or systemic infection

          -  Anemia

          -  History of asthma likely to require systemic steroid therapy

          -  Autoimmune connective tissue disorders or immunocompromised

          -  History of malignancy except non-melanoma skin cancer

          -  Continuous use of ulcerogenic medication

          -  On anticoagulation or antiplatelet therapy

          -  Use of weight-loss medication

          -  In other weight-loss program

          -  Unable to take proton pump inhibitor

          -  Abnormal laboratory values or EKG

          -  Inability to walk at least 0.8 kilometers per day

          -  Planned surgical procedure that can impact the conduct of the study

          -  Known allergy to any component materials in the TPSS

          -  Smoker or user of nicotine product

          -  Substance abuse

          -  Severe, uncontrolled psychiatric illness

          -  Recent inpatient psychiatric treatment

          -  Moderate depression

          -  Bulimia nervosa or binge eating disorder

          -  Participation in another clinical study

          -  Employee or family member of Sponsor or study staff

          -  Have any endoscopic exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard I Rothstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth Geisel School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HonorHealth Bariatric Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidSouth Bariatrics</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <results_first_submitted>April 20, 2019</results_first_submitted>
  <results_first_submitted_qc>July 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2019</results_first_posted>
  <disposition_first_submitted>January 14, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 14, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 17, 2019</disposition_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Device</keyword>
  <keyword>Non-surgical</keyword>
  <keyword>Endoscopic</keyword>
  <keyword>TransPyloric Shuttle</keyword>
  <keyword>TPS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02518685/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TransPyloric Shuttle (TPS)</title>
          <description>TransPyloric Shuttle plus lifestyle counseling</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Sham procedure plus lifestyle counseling.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Cohort</title>
              <participants_list>
                <participants group_id="P1" count="203">Randomized to and successfully received TPS (171) + Open-Label TPS-treated Subjects (32)</participants>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized Cohort</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="213">Includes 171 Successful device deployments, 10 unsuccessful delivery attempts and 32 Open-Label</participants>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Analysis</title>
              <participants_list>
                <participants group_id="P1" count="168">Three TPS-treated subjects were inadvertently unblinded, excluding them from efficacy analyses.</participants>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164">Randomized Completers (139) plus Open-Label Completers (25)</participants>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>relocation, study fatigue</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TransPyloric Shuttle (TPS)</title>
          <description>TransPyloric Shuttle plus lifestyle counseling</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Sham procedure plus lifestyle counseling.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="181"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="270"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="8.9"/>
                    <measurement group_id="B2" value="43.9" spread="8.5"/>
                    <measurement group_id="B3" value="43.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group</title>
        <description>The mean percent Total Body Weight Loss (% TBL) is the percentage weight change at 12 Months from Baseline</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TransPyloric Shuttle (TPS)</title>
            <description>TransPyloric Shuttle plus lifestyle counseling
TransPyloric Shuttle
lifestyle counseling</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Sham procedure plus lifestyle counseling.
lifestyle counseling
Sham procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group</title>
          <description>The mean percent Total Body Weight Loss (% TBL) is the percentage weight change at 12 Months from Baseline</description>
          <units>% Total Body Weight Loss</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="0.65"/>
                    <measurement group_id="O2" value="2.8" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>multiple imputations</method>
            <param_type>Least-Square Mean Difference</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.54</ci_lower_limit>
            <ci_upper_limit>8.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of TPS-treated Subjects With Weight Loss ≥ 5% TBL</title>
        <description>The proportion of subjects in the TPS group with ≥ 5% TBL is compared to a performance target of 50%</description>
        <time_frame>12 months</time_frame>
        <population>Per Protocol Population; received TPS Device</population>
        <group_list>
          <group group_id="O1">
            <title>TransPyloric Shuttle (TPS)</title>
            <description>TransPyloric Shuttle plus lifestyle counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of TPS-treated Subjects With Weight Loss ≥ 5% TBL</title>
          <description>The proportion of subjects in the TPS group with ≥ 5% TBL is compared to a performance target of 50%</description>
          <population>Per Protocol Population; received TPS Device</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Statistical success criterion for achieving the performance standard of (≥ 50%) of proportion of TPS subjects who have 5% or more TBL at the 12-Month Follow-up</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Wilson's Midpoint Estimate</method>
            <param_type>Proportion of Subjects</param_type>
            <param_value>66.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.3</ci_lower_limit>
            <ci_upper_limit>74.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>The TPS, SAE population includes all subjects successful deliveries plus 10 subjects with attempted deliveries.
The TPS, AE population includes successful deliveries where the TPS remained for up to one year</desc>
      <group_list>
        <group group_id="E1">
          <title>TransPyloric Shuttle (TPS)</title>
          <description>TransPyloric Shuttle plus lifestyle counseling</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Sham procedure plus lifestyle counseling.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>esophageal rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>upper abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>gastric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>divericularitis</sub_title>
                <description>not device or procedure related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>device intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholelithiasis</sub_title>
                <description>not device or procedure related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>meningioma</sub_title>
                <description>not device or procedure related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <description>not device or procedure related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumothorax</sub_title>
                <description>due to esophageal rupture in same patient</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>eructation</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>gastritis, erosive</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>gastric mucosa erythema</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>esophageal mucosal injury</sub_title>
                <description>endoscopic observations during procedure</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lian Cunningham, MD, PhD</name_or_title>
      <organization>BAROnova, Inc</organization>
      <phone>650.638.9796 ext 22</phone>
      <email>lcunningham@baronova.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

